AstraZeneca-Oxford University's COVID-19 vaccine shows average efficacy of 70%, says manufacturer

Additionally, the drug manufacturer said that another regiment of a half dose, followed by a full dose at least one month apart was 90 percent effective

The Associated Press November 23, 2020 16:03:28 IST
AstraZeneca-Oxford University's COVID-19 vaccine shows average efficacy of 70%, says manufacturer

Representational image. NHS

London: AstraZeneca said Monday that late-stage trials showed that its COVID-19 vaccine with Oxford University was up to 90 percent effective in preventing disease.

The results are based on interim analysis of trials in the UK and Brazil of a vaccine developed by Oxford University and manufactured by AstraZeneca. No hospitalisations or severe cases of COVID-19 were reported in those receiving the vaccine, AstraZeneca said.

The trial looked at two different dosing regimens. A half dose of the vaccine followed by a full dose at least one month apart was 90 percent effective. A second regimen using two full doses one month apart was 62 percent  effective. The combined results showed an average efficacy rate of 70 percent.

"These findings show that we have an effective vaccine that will save many lives," Professor Andrew Pollard, chief investigator for the trial, said in a statement. "Excitingly, we’ve found that one of our dosing regimens may be around 90 percent effective.’"

AstraZeneca is the third major drug company to report late-stage results for its potential COVID-19 vaccine as public health officials around the world anxiously wait for vaccines that will end the pandemic that has killed almost 1.4 million people. Pfizer and Moderna last week reported preliminary results from late-stage trials showing their vaccines were almost 95 percent effective.

Yet unlike many of its rivals, the AstraZeneca-Oxford vaccine does not have to be stored at ultra-cold temperatures, making it far easier to distribute in developing countries.

AstraZeneca CEO Pascal Soriot said the simple supply chain for AstraZeneca’s vaccine and the company’s commitment to provide it on a non-profit basis during the pandemic mean it will be affordable and available to people around the world.

“This vaccine’s efficacy and safety confirm that it will be highly effective against COVID-19 and will have an immediate impact on this public health emergency,’’ Soriot said.

The results come as COVID-19 infection rates are rising in most U.S. states and in many countries amid a resurgence of the virus that is once again prompting governments to shut down businesses and restrict social gatherings around the world. England is still in the middle of a four-week lockdown that has closed all non-essential shops, while in the U.S., the government's top health agency has recommended that Americans not travel to visit family and friends over the Thanksgiving holiday this week.

Now that AstraZeneca has released its interim results, regulators must approve the vaccine before it can be widely distributed.

Britain has ordered 100 million doses of the Oxford vaccine, and the government says several million doses can be produced before the end of the year if it gains approval from the regulator.

British Health Secretary Matt Hancock said he felt “a great sense of relief” at the news of the AstraZeneca vaccine’s effectiveness.

He said just months ago, as the virus raged, “the idea that by November we would have three vaccines, all of which have got high effectiveness … I would have given my eye teeth for.”

Updated Date:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

Disappointing results from Chinese CoronaVac trial pose a setback for developing nations
science

Disappointing results from Chinese CoronaVac trial pose a setback for developing nations

Many nations that have ordered CoronaVac are relatively poor, desperate to halt the pandemic and protect their population.

COVID-19 vaccination: 447 recipients across India suffer adverse events post inoculation; how AEFI is tracked, reported
India

COVID-19 vaccination: 447 recipients across India suffer adverse events post inoculation; how AEFI is tracked, reported

With COVID-19 making the immunisation of adults necessary, the Centre has involved cardiologists, neurologists, general physicians, and pulmonologists in the AEFI committees at national, state, and district levels

Coronavirus News Updates: Bharat Biotech says Bhopal volunteer who died 10 days after trial jab was 'healthy' in follow-ups
Health

Coronavirus News Updates: Bharat Biotech says Bhopal volunteer who died 10 days after trial jab was 'healthy' in follow-ups

Coronavirus News LIVE Updates: A 42-year-old volunteer from Bhopal died nearly ten days after he participated in the clinical trial for Covaxin; poisoning is suspected but officials said that the exact cause of the death will be known after viscera test